Alexandra M Mowday Selected Research

Prodrugs

11/2023	Design and Biological Evaluation of Piperazine-Bearing Nitrobenzamide Hypoxia/GDEPT Prodrugs: The Discovery of CP-506.
2/2022	Interrogation of the Structure-Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications.
12/2021	Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506.
1/2019	Engineering Escherichia coli NfsB To Activate a Hypoxia-Resistant Analogue of the PET Probe EF5 To Enable Non-Invasive Imaging during Enzyme Prodrug Therapy.
3/2017	Engineering a Multifunctional Nitroreductase for Improved Activation of Prodrugs and PET Probes for Cancer Gene Therapy.
6/2016	Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress.
1/2016	Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
10/2015	Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility.
2/2014	Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.
6/2013	Pseudomonas aeruginosa NfsB and nitro-CBI-DEI--a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alexandra M Mowday Research Topics

Disease

16	Neoplasms (Cancer) 02/2024 - 03/2012
8	Hypoxia (Hypoxemia) 11/2023 - 03/2012
3	Disease Progression 03/2017 - 02/2014
2	Necrosis 02/2024 - 01/2022
1	Bacterial Infections (Bacterial Infection) 02/2024
1	Colonic Neoplasms (Colon Cancer) 01/2022
1	Brain Neoplasms (Brain Tumor) 06/2020
1	Colorectal Neoplasms (Colorectal Cancer) 01/2016
1	Carcinoma (Carcinomatosis) 04/2013

Drug/Important Bio-Agent (IBA)

12	ProdrugsIBA 11/2023 - 03/2012
6	EnzymesIBA 01/2019 - 04/2013
5	NitroreductasesIBA 02/2022 - 04/2013
4	PR-104AIBA 11/2023 - 11/2021
2	Phosphates (Orthophosphate)IBA 02/2022 - 01/2016
2	Oxidoreductases (Dehydrogenase)IBA 11/2021 - 02/2014
2	azomycinIBA 01/2019 - 03/2012
1	Interferon Type IIBA 02/2024
1	SolutionsIBA 02/2024
1	Immune Checkpoint InhibitorsIBA 02/2024
1	Interleukin-2 (IL2)IBA 02/2024
1	PiperazineIBA 11/2023
1	Aldo-Keto ReductasesIBA 11/2023
1	Mesylates (Mesylate)IBA 11/2023
1	vadimezanIBA 01/2022
1	A-Form DNA (A-DNA)IBA 12/2021
1	Antineoplastic Agents (Antineoplastics)IBA 12/2021
1	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 11/2021
1	LuciferasesIBA 06/2020
1	Temozolomide (Temodar)FDA LinkGeneric 06/2020
1	SN33623IBA 01/2019
1	4-nitroimidazoleIBA 01/2019
1	SN34507IBA 01/2016
1	PR-104IBA 01/2016
1	SN35539IBA 01/2016
1	Coordination ComplexesIBA 02/2014
1	Cytotoxins (Cytolysins)IBA 02/2014
1	Nitro CompoundsIBA 02/2014
1	OxidesIBA 02/2014
1	Oxygen (Dioxygen)IBA 02/2014
1	QuinonesIBA 02/2014
1	Proteins (Proteins, Gene)FDA Link 04/2013
1	isophosphamide mustard (IPAM)IBA 03/2012
1	TH 302IBA 03/2012
1	NucleotidesIBA 03/2012
1	DNA (Deoxyribonucleic Acid)IBA 03/2012

Therapy/Procedure

8	Therapeutics 02/2024 - 04/2013
4	Immunotherapy 02/2024 - 01/2021
1	Immunomodulation 02/2024
1	Radiotherapy 02/2014